Spruce Biosciences, Inc. (SPRB)
NASDAQ: SPRB · Real-Time Price · USD
54.94
-3.61 (-6.17%)
At close: Feb 27, 2026, 4:00 PM EST
55.91
+0.97 (1.77%)
After-hours: Feb 27, 2026, 7:33 PM EST
Spruce Biosciences Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Spruce Biosciences stock have an average target of 187.9, with a low estimate of 37.5 and a high estimate of 283. The average target predicts an increase of 242.01% from the current stock price of 54.94.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Spruce Biosciences stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Buy | 0 | 1 | 1 | 3 | 3 | 3 |
| Hold | 5 | 5 | 5 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $220 → $200 | Strong Buy | Maintains | $220 → $200 | +264.03% | Feb 19, 2026 |
| Oppenheimer | Oppenheimer | Buy Initiates $283 | Buy | Initiates | $283 | +415.11% | Dec 23, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $220 | Strong Buy | Initiates | $220 | +300.44% | Dec 22, 2025 |
| Leerink Partners | Leerink Partners | Hold → Buy Upgrades $160 | Hold → Buy | Upgrades | $160 | +191.23% | Dec 3, 2025 |
| Citizens | Citizens | Buy Maintains $254 → $259 | Buy | Maintains | $254 → $259 | +371.42% | Nov 11, 2025 |
Financial Forecast
Revenue This Year
n/a
from 4.91M
Revenue Next Year
54.84M
EPS This Year
-22.07
from -96.39
EPS Next Year
-23.11
from -22.07
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | n/a | 158.0M | |
| Avg | n/a | 54.8M | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -2.90 | 20.96 | |
| Avg | -22.07 | -23.11 | |
| Low | -56.01 | -48.48 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.